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Abstract
Background: Infectious disease (ID) consultations have been shown to increase adherence to guidelines and
decrease mortality for patients with Staphylococcus aureus bacteremia (SAB). Here, we assessed the impact of a
mandatory ID consultation policy for SAB.
Methods: We retrospectively reviewed all consecutive adult patients with SAB at two tertiary care teaching
hospitals in Hamilton, ON, Canada. Mandatory ID consults for SAB were implemented on January 1st 2012. We
compared SAB cases in 2011 (control group) with those in 2012 (intervention group). Outcomes included
adherence to the Infectious Diseases Society of America guidelines and patient outcomes.
Results: We reviewed 128 SAB cases in 2011 and 124 in 2012. The majority of S. aureus were methicillin-susceptible
(97/128, 75.8 % in 2011 and 100/124, 80.6 % in 2012). ID involvement increased significantly from 93/128 (72.7 %) in
2011, to 103/124 (83.1 %) in 2012 (odds ratio [OR] 1.9, 95 % confidence interval [CI] 1.1–3.3, p = 0.047). There was
also a significant decrease in the median time to ID involvement from 2 days to 1 (p = 0.001). In patients who
survived the minimum treatment course (greater than 13 days), there was a significant improvement in adherence
to IDSA guidelines in 2012 (65/102, 63.7 % vs. 77/96, 80.2 %; OR 2.3, 95 % CI 1.2–4.4, p = 0.01). Mortality and SAB
relapse rates were similar in both groups.
Conclusions: Creating an automated ID consultation for SAB led to an increase in involvement of ID, a significant
decrease in time to ID involvement, and better adherence to IDSA guidelines. The study was not sufficiently
powered to detect significant changes in mortality and SAB relapse rates.
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Background
Staphylococcus aureus (S. aureus) bacteremia (SAB) is well
described to cause significant cost, morbidity and mortal-
ity [1–6]. Current guidelines, including the guidelines by
the Infectious Diseases Society of America (IDSA), detail
the need for immediate intervention and further diagnos-
tic evaluation when SAB is identified [7–9]. These include:
appropriate choice and duration of antimicrobial therapy,
evaluation for metastatic infection including endocarditis
and the removal of infected foci. When conducted in a
timely fashion these strategies have been shown to improve
morbidity and mortality [2, 3, 7, 9–18]. Prior studies have
illustrated that involvement of the Infectious Disease (ID)
consultation service increases adherence to evidence-based
treatment [2–4, 12–18] and in a number of studies has led
to decreased mortality [2, 15, 16, 18 ]. Apart from a few
studies, ID involvement has been at the discretion of the
most responsible physician, and therefore their findings
may be affected by a selection (i.e. referral) bias [14–17].
The purpose of this study was to determine whether a
policy mandating an automatic ID consultation in patients
* Correspondence: mertzd@mcmaster.ca
1Department of Medicine, McMaster University, Hamilton, ON, Canada
3Hamilton Health Sciences, Juravinski Hospital and Cancer Center, 711
Concession Street, Section M, Level 1, Room 3, Hamilton, ON L8V 1C3,
Canada
Full list of author information is available at the end of the article
© 2015 Martin et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Martin et al. BMC Infectious Diseases  (2015) 15:568 
DOI 10.1186/s12879-015-1296-y
with SAB improves adherence to evidence-based guide-
lines and patient outcomes.
Methods
This study was conducted at two tertiary care teaching
hospital sites of Hamilton Health Sciences, in Hamilton,
Ontario, Canada. Patients with positive cultures from
these sites were flagged at the level of the laboratory and
collected for screening for enrollment in the study. Eth-
ics approval was received from the Hamilton Integrated
Research Ethics Board.
All consecutive adult patients (≥18 years of age) with
an episode of SAB defined as the isolation of S. aureus
from one or more blood culture samples were included
[7, 8]. Only the first episode of SAB during the study
period was included. We excluded patients in whom we
could not obtain information about their therapy due to
transfer to another hospital, outpatient cultures with no
documentation of therapy, positive cultures from path-
ology, and patients who left the hospital against medical
advice early in their therapy.
In this non-controlled quasi-experimental study, we
included positive cultures meeting inclusion criteria
from January 1, 2011 to December 31, 2011 as the con-
trol group prior to the implementation of an automated
infectious disease consultation policy. The intervention
group included positive cultures meeting inclusion cri-
teria from January 1, 2012 to December 31, 2012. The
policy implemented on January 1st 2012 mandated ID
consultation for all in-patients with SAB. The microbiol-
ogy laboratory technologist reported detection of any
positive blood culture for S. aureus to the most respon-
sible physician and directly to the ID physician on call.
The ID service was required to assess the current anti-
biotic treatment of in-patients with SAB within one hour
and to complete a formal consult within 24 h of notifica-
tion to guide management. Management was to follow
an evidence-based approach as summarized in the pol-
icy, and ID was expected to follow the patient until there
was complete resolution or patient discharge.
The primary outcome was pre-specified as adherence
to guidelines in the management of SAB, as outlined in
the internal policy, which was based on published guide-
lines [7, 8]. This outcome was defined as a composite of
appropriate duration, dose, route, and spectrum of anti-
biotics, obtaining follow-up blood cultures within 3 days,
completion of a TEE and/or TTE, and obtaining source
control when indicated. Correct duration of antibiotics
was defined as 14 +/− 2 days for uncomplicated SAB or
28-42 +/− 2 days for complicated SAB [7, 8]. Antibiotic
duration was only counted as appropriate if clinicians
had selected an antibiotic that would adequately treat S.
aureus as per the guideline and policy, inclusive of cefa-
zolin, cloxacillin, vancomycin, or daptomycin.
Secondary outcomes included in-hospital mortality,
clearance of SAB defined as no relapse of SAB within
30 days after discontinuing antibiotics, re-admission de-
fined as hospital admission within 30 days of discharge,
and time to ID involvement. Patients discharged on anti-
biotics were deemed to have cleared SAB unless they
were re-admitted with a relapse of SAB.
Categorical data was analyzed using Chi-square, non-
categorical data using Student’s T-test or Mann–Whitney
U-test as appropriate (PASW Version 18, Chicago, IL).
Results
A total of 128 cases of S. aureus bacteremia from 2011
and 124 from 2012 were included (Fig. 1). The majority
of these cases were methicillin-susceptible (MSSA; 75.8
and 80.6 % respectively, Table 1). Both centers com-
bined, the rate of ID consultation increased significantly
between 2011 and 2012 from 72.7 to 83.1 % (odds ratio
[OR] 1.9, 95 % confidence interval [CI] 1.1–3.3, p =
0.047), an effect that was driven by the one center with a
low ID involvement rate at baseline (hospital 2, 54.2 to
78.3 %, OR 3.0, 1.4–10.0, p = 0.005). The time to con-
sultation was significantly reduced from 2 days to 1 day
(p = 0.001).
Overall, adherence to the guidelines improved from
63.7 to 80.2 % (OR 2.3, 95 % CI 1.2–4.4, p = 0.01) in
268 Patients Screened for positive cultures s. aureus
132 cases in 2011 136 cases in 2012
128 included in final 
mortality analysis







2 Culture from 2010
12 cases excluded:





2 Transferred to 
another institution 
with no records
1 Patient refused 
treatment
5 Palliative Cases
21 Patients did not survive 
the minimum treatment 
period (13 days)
8 Palliative Cases
20 Patients did not survive 
the minimum treatment 
period (13 days)
102 Final Adherence 
Analysis
96 Final Adherence 
Analysis
Fig. 1 Study inclusion and outcomes. Abbreviations: s. aureus:
Staphylococcus aureus; AMA: against medical advice
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patients that survived the minimum treatment course
(greater than 13 days). Again, this result was driven by
the hospital with the lower baseline adherence
(57.4 to 78.3 %, OR 2.7, 95 % CI 1.1–6.6, p = 0.03)
(Table 2). The primary cause of deviation from guide-
lines included: the lack of TTE or TEE (14.7 % in
2011, 7.3 % in 2012) and the lack of follow up blood
cultures (12.7 % in 2011, 10.4 % in 2012). The pro-
portion of patients with guideline-incongruent antibi-
otics treatment duration improved from 2011 to 2012
(11.8 % in 2011 to 3.1 % in 2012, OR 0.24, 95 % CI
0.07–0.88, p = 0.02). There was a trend towards lower
rates of TTE/TEE in hospital-acquired cases, defined
as positive blood cultures on day 3 of hospital admis-
sion or later: TTE/TEE was conducted in 121/129 of
community-acquired SAB cases in both 2011 and
2012 (93.8 %) in comparison to 55/69 (79.7 %) of
hospital-acquired SAB. Of note, the proportion of
cases with non-adherence to more than one guideline
recommendation decreased significantly from 2011 to
2012 (11.8 to 3.1 %, OR 0.24, 95 % CI 0.07–0.89, p = 0.02).
The ID consultation service was involved in 92.3 % of
cases in 2011 and 93.5 % of cases in 2012 in which there
was adherence to guidelines.
Table 1 Patient characteristics of the baseline and intervention patient population
2011 (Baseline) 2012 (Intervention) Odds ratio (95 % CI) P value
Total n 128 124
Age 63.4 62.8 0.29
Male 74 (57.8 %) 74 (59.7 %) 1.1 (0.7–1.7) 0.76
Hospital 1 (vs. Hospital 2) 69 (53.9 %) 64 (51.6 %) 0.9 (0.6–1.5) 0.71
MSSA (vs. MRSA) 97 (75.8 %) 100 (80.6 %) 1.3 (0.7–2.4) 0.35
Palliative 5 (3.9 %) 8 (6.5 %) 1.7 (0.5–5.3) 0.36
ID Involvement
Overall 93/128 (72.7 %) 103/124 (83.1 %) 1.9 (1.1–3.3) 0.047
Hospital 1 61/69 (88.4 %) 56/64 (87.5 %) 0.9 (0.3–2.5) 0.87
Hospital 2 32/59 (54.2 %) 47/60 (78.3 %) 3.0 (1.4–10.0) 0.005
Time to ID Involvement
Days, median (IQR) 2 (1–3) 1 (1–2) n/a 0.001
Mortality
Overall 37/128 (28.9 %) 35/124 (28.2 %) 0.97 (0.6–1.7) 0.91
Palliative cases excluded 34/123 (27.6 %) 31/116 (26.7 %) 0.96 (0.5–1.7) 0.87
Relapse 0 0 n/a n/a
Readmission 1/128 (0.01 %) 1/124 (0.01 %) 1.0 (0.6–16.7) 0.98
Abbreviations: MSSA methicillin susceptible Staphylococcus aureus, MRSA methicillin Resistant Staphylococcus aureus, CI confidence interval, ID Infectious Disease,
IQR interquartile range, n/a not applicable
Table 2 Outcomes of the control and intervention patient population in non-palliative patients who survived the minimum treatment
period (at least 13 days)
Adherence to IDSA Guidelines
2011 (Baseline) 2012 (Intervention) Odds ratio (95 % CI) P value
Overall 65/102 (63.7 %) 77/96 (80.2 %) 2.3 (1.2–4.4) 0.01
Hospital 1 38/55 (69.1 %) 41/50 (82 %) 2.1 (0.8–5.1) 0.12
Hospital 2 27/47 (57.4 %) 36/46 (78.3 %) 2.7 (1.1–6.6) 0.03
Reason for non-adherence to guidelines
No TTE 15/102 (14.7 %) 7/96 (7.3 %) 0.46 (0.18–1.17) 0.10
No Follow-up cultures 13/102 (12.7 %) 10/96 (10.4 %) 0.80 (0.33–1.91) 0.61
Inappropriate Antibiotic Duration 12/102 (11.8 %) 3/96 (3.1 %) 0.24 (0.07–0.88) 0.02
No source control (cases with source) 1/66 (1.5 %) 0/61 (0.0 %) 0.99 (0.96–1.01) 0.34
Greater than one of the above reasons for non–adherence to guidelines 12/102 (11.8 %) 3/96 (3.1 %) 0.24 (0.07–0.89) 0.02
Abbreviations: IDSA infectious disease society of America, CI confidence interval, TTE trans-thoracic echocardiogram
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Despite the notable difference in adherence to guide-
lines when comparing the 2 years, we did not detect a
difference in mortality once palliative cases were
excluded (Table 1: 27.6 % in 2011 and 26.7 % in 2012,
OR 0.96, 95 % CI 0.5–1.7, p = 0.87). A survival analysis
showed no difference in the time to death comparing
the two groups (Log Rank test, p = 0.674). There were
no relapses and only two SAB-related re-admissions,
thus no difference between the control and intervention
group could be found.
In terms of choice of antibiotics, the proportion of pa-
tients who did not receive empiric vancomycin in
addition to cefazolin or cloxacillin decreased signifi-
cantly between 2011 and 2012 (13.7-3.1 %, OR 0.20,
95 % CI 0.06–0.73, p = 0.01 (Table 3). A total of 72 pa-
tients (28.6 %) received therapeutic courses of vanco-
mycin for 3 days or more. Of those patients, the average
course of vancomycin was 14.5 days and the average
time to the first trough level was 3.14 days. The first
trough level was therapeutic (15–20) in only 8 patients
(11.1 %), significantly sub-therapeutic (<10) in 23 (31.9 %),
and too high (>20) in 12 cases (16.7 %). Similarly, of those
that remained on vancomycin long enough to receive a
third trough level, 8 patients (25.8 %) were therapeutic
with trough levels 15–20, whereas trough levels were too
high (>20) in 18 patients (58.1 %). This highlights the
challenge in achieving and maintaining therapeutic trough
levels when treating patients with vancomycin.
Discussion
We found an increase in adherence to published guide-
lines in the management of S. aureus bacteremia upon
the initiation of an automated infectious disease consult-
ation. However, there was no statistical improvement in
patient outcomes.
There was a particularly high rate of baseline ID in-
volvement when compared to other published studies.
Jenkins et al. performed a similar before/after study in
2005 and had a baseline consultation rate of 53 % [14],
whereas, in our study ID involvement was 54.2 and
88.4 % at our two hospital sites, respectively, prior to the
intervention (overall rate 72.7 %). It is unclear why the
rate of baseline ID involvement was significantly higher
at one of our hospitals. It is possible that the practice
pattern dictated this difference. As well, there are two
distinct ID services at the hospital with higher baseline
consultation rates (an immune-compromised and immune-
competent service), which may increase accessibility to ID
consultation. Despite the considerable rate of ID involve-
ment at baseline, this study illustrated a significant reduc-
tion in time to ID consultation at the two sites combined
(2 days in comparison to 1 day, p = 0.001). Overall, this
highlights that the impact of a mandatory ID consult pol-
icy is dependent upon the practice pattern at the hospital
where it is initiated.
The increase in adherence to guidelines between 2011
and 2012 was 16.4 % while the increase in ID consult-
ation was 10.4 %. It is possible that the institution of a
mandated consultation led to increased awareness around
guideline-based management of s. aureus bacteremia both
by the ID physicians as well as the most responsible physi-
cians, which would have contributed further to the overall
improvement in adherence to guidelines.
Following the intervention, it is unclear why the rate
of ID involvement did not increase to one hundred per-
cent, as would have been expected. Seven patients
passed away within 72 h and five patients were palliated,
which likely explains the lack of formal consultation. We
cannot find an explanation for the remaining nine cases,
however. It is possible that the staff physician reviewed
the antibiotics and management with the care team
upon being notified by the lab and never completed the
formal consult, or planned to complete the formal con-
sult however details were lost in handover.
Multiple previous studies have illustrated a mortality
benefit from a similar intervention [2, 15, 16, 18]. The
lack of difference in mortality in our study may be ex-
plained partially by our small sample size and potential
confounding factors. Further, the overall high baseline
rate of ID involvement and the relatively high level of
adherence to guidelines at baseline may mask a potential
effect. For example, in the study by Nagao et al. the
baseline rate of TTE/TEE use prior to ID involvement
was 37.1 % [15] and Jenkins et al. found a baseline rate of
57 % [14]. In our study the baseline use of echocardiogram
prior to the intervention was 85.3 %. We found a very
Table 3 Empiric therapy used in treatment of suspected SAB
Empiric therapy 2011 (Baseline) 2012 (Intervention) Odds ratio (95 % CI) P value
Solely Cefazolin or Cloxacillin 14/102 (13.7 %) 3/96 (3.1 %) 0.20 (0.06–0.73) 0.01
Solely Vancomycin 32/102 (31.4 %) 36/96 (37.5 %) 1.31 (0.73–2.36) 0.36
Vancomycin + Cefazolin/Cloxacillin 14/102 (13.7 %) 22/96 (22.9 %) 1.87 (0.89–3.91) 0.09
Vancomycin + other beta-lactam 30/102 (29.4 %) 24/96 (25 %) 0.80 (0.43–1.50) 0.49
No therapy 2/102 (2.0 %) 0/96 0.98 (0.96–1.01) 0.17
Other empiric therapy 10/102 (9.8 %) 11/96 (11.5 %) 1.19 (0.48–2.45) 0.71
Abbreviation: CI confidence interval
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high rate of echocardiogram completion in community-
acquired cases (93.8 %) with a lower rate (79.7 %) in
hospital-acquired cases.
Our study differs from a number of previous studies
published on this subject (Additional file 1: Table S1).
Bai et al. and Fowler et al. had a similar study question,
however ID consultations were offered rather than man-
dated thus could have led to a selection bias [4, 18].
Nagao et al. similarly developed a mandatory consult-
ation process, however in Japan they note that ID con-
sultation was rare for bloodstream infections and that
the ID staff could not prescribe antibiotics themselves
[15]. Jenkin et al. created a mandatory consultation,
however, their results were underpowered and they note
that there was no specific algorithm for the evaluation
and management of SAB at the time of the study [14].
Most recently, Saunderson et al. published a study with
mandatory ID consultations in SAB [17]. Their control
arm prior to the mandatory ID consult had the benefit
of phone advice from a microbiologist, which is not
standard practice in many institutions.
Thus, our study offers a different perspective on a
mandatory ID consultation policy. The main limitation
of our study was the retrospective design with data col-
lection from a chart review, which provides a potential
for immeasurable confounding factors between the be-
fore and after patient population and relies on clear
documentation from the healthcare team.
Conclusion
The institution of an automated ID consultation for SAB
led to an increase in involvement of ID, a significant
decrease in time to ID involvement, and improved
adherence to IDSA guidelines. However, we did not detect
a difference in mortality due to this intervention in our
study. Our study further adds to the growing volume
of published evidence demonstrating improvement in
management of SAB when ID services are involved.
Additional file
Additional file 1: Overview of studies evaluating the impact of
antimicrobial stewardship on management and outcomes of
Staphylococcus aureus bacteremia. (DOCX 21 kb)
Abbreviations
CI: Confidence interval; ID: Infectious disease; IDSA: Infectious diseases society
of America; IQR: Interquartile range; MRSA: Methicillin resistant
Staphylococcus aureus; MSSA: Methicillin susceptible Staphylococcus aureus;
n/a: not applicable; OR: Odds ratio; S. aureus: Staphylococcus aureus;
SAB: Staphylococcus aureus bacteremia.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LM participated in data collection, led the statistical analysis of data under
supervision of DM and was responsible for drafting of the manuscript. MTH
was involved in writing and developing the study protocol, participated in
data collection and helped with critical revisal of the manuscript. AB was
involved in developing the study protocol and critical review of the
manuscript. CM was involved in developing the study protocol, facilitated
the implementation of the policy from the laboratory perspective, provided
the list of SAB patients, and critically reviewed the manuscript. DM
conceived of the study, oversaw the development of the protocol and data
collection, supervised statistical analysis and helped to draft and edit the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
DM is a recipient of a Research Early Career Award from Hamilton Health
Sciences Foundation (Jack Hirsh Fellowship).
Funding
This study was supported by an unrestricted educational grant from
Sunovion Pharmaceuticals Canada Inc.
Author details
1Department of Medicine, McMaster University, Hamilton, ON, Canada.
2Department of Medicine, University of British Columbia, Vancouver, BC,
Canada. 3Hamilton Health Sciences, Juravinski Hospital and Cancer Center,
711 Concession Street, Section M, Level 1, Room 3, Hamilton, ON L8V 1C3,
Canada. 4Department of Pathology and Laboratory Medicine, McMaster
University, Hamilton, ON, Canada. 5Department of Clinical Epidemiology and
Biostatistics, McMaster University, Hamilton, ON, Canada. 6Michael G.
DeGroote, Institute for Infectious Diseases Research, McMaster University,
Hamilton, ON, Canada.
Received: 3 August 2015 Accepted: 26 November 2015
References
1. Robinson JO, Pearson JC, Christiansen KJ, Coombs GW, Murray RJ.
Community-associated versus healthcare-associated methicillin-resistant
Staphylococcus aureus bacteraemia: a 10-year retrospective review. Eur J
Clin Microbiol Infect Dis. 2009;28:353–61.
2. Robinson JO, Pozzi-Langhi S, Phillips M, Pearson JC, Christiansen KJ,
Coombs GW, et al. Formal infectious diseases consultation is associated
with decreased mortality in Staphylococcus aureus bacteraemia. Eur J Clin
Microbiol Infect Dis. 2012;31:2421–8.
3. Honda H, Krauss MJ, Jones JC, Olsen MA, Warren DK. The value of infectious
diseases consultation in Staphylococcus aureus bacteremia. Am J Med.
2010;123:631–7.
4. Fowler VG Jr, Sanders LL, Sexton DJ, Kong L, Marr KA, Gopal AK, et al.
Outcome of Staphylococcus aureus bacteremia according to compliance
with recommendations of infectious diseases specialists: experience with
244 patients. Clin Infect Dis. 1998;27:478–86.
5. Mylotte JM, Tayara A. Staphylococcus aureus bacteremia: predictors of
30-day mortality in a large cohort. Clin Infect Dis. 2000;31:1170–4.
6. Beeston CJ, Gupta R, Chadwick PR, Young RJ. Methicillin-resistant
Staphylococcus aureus bacteraemia and mortality in a teaching hospital.
Eur J Clin Microbiol. 2009;28:585–90.
7. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, TöröK ME, et al.
Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis.
2011;11(3):208–22.
8. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical
practice guidelines by the infectious diseases society of america for the
treatment of methicillin-resistant Staphylococcus aureus infections in adults
and children. Clin Infect Dis. 2011;52:18–55.
9. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, et al.
Infective endocarditis: diagnosis, antimicrobial therapy, and management of
complications: a statement for healthcare professionals from the committee
on rheumatic fever, endocarditis, and Kawasaki disease, council on
cardiovascular disease in the young, and the councils on clinical cardiology,
stroke, and cardiovascular surgery and anesthesia, american heart association:
endorsed by the infectious diseases society of america. Circulation. 2005;
111(23):394–434.
Martin et al. BMC Infectious Diseases  (2015) 15:568 Page 5 of 6
10. Chang FY, Peacock Jr JE, Musher DM, Triplett P, MacDonald BB,
Mylotte JM, et al. Staphylococcus aureus bacteremia: recurrence and
the impact of antibiotic treatment in a prospective multicenter study.
Medicine (Baltimore). 2003;82:333–9.
11. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical
practice guidelines for the diagnosis and management of intravascular
catheter-related infection: 2009 update by the infectious diseases society of
america. Clin Infect Dis. 2009;49:1–45.
12. Pragman AA, Kuskowski MA, Abraham JM, Filice GA. Infectious disease
consultation for staphylococcus aureus bacteremia improves patient
management and outcomes. Infect Dis Clin Pract. 2012;20:261–7.
13. López Cortés LE, Del Toro MD, Gálvez-Acebal J, Bereciartua Bastarrica E,
Fariñas MC, Sanz-Franco M, et al. Impact of an evidence-based bundle
intervention in the quality-of-care management and outcome of
Staphylococcus aureus bacteremia. Clin Infect Dis. 2013;57:1225.
14. Jenkins TC, Price CS, Sabel AL, Mehler PS, Burman WJ. Impact of routine
infectious diseases service consultation on the evaluation, management,
and outcomes of Staphylococcus aureus bacteremia. Clin Infect Dis.
2008;46:1000–8.
15. Nagao M, Iinuma Y, Saito T, Matsumura Y, Shirano M, Matsushima A, et al.
Close cooperation between infectious disease physicians and attending
physicians can result in better management and outcome for patients with
Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2010;16:1783–8.
16. Tissot F, Calandra T, Prod’hom G, Taffe P, Zanetti G, Greub G, et al.
Mandatory infectious disease consultation for MRSA bacteremia is
associated with reduced mortality. J Infect. 2014;69:226–34.
17. Saunderson RB, Gouliouris T, Nickerson EK, Cartwright EJ, Kidney A,
Aliyu SH, et al. Impact of routine bedside infectious disease consultation
on clinical management and outcome of Staphylococcus aureus bacteraemia
in adults. Clin Microbiol Infect. 2015;21(8):779–85.
18. Bai AD, Showler A, Burry L, Steinberg M, Ricciuto DR, Fernandes T, et al.
Impact of Infectious Disease Consultation on Quality of Care, Mortality, and
Length of Stay in Staphylococcus aureus Bacteremia: Results From a Large
Multicenter Cohort Study. Clin Infect Dis. 2015;60(10):1451–61.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Martin et al. BMC Infectious Diseases  (2015) 15:568 Page 6 of 6
